Skip to main content
. Author manuscript; available in PMC: 2016 Dec 19.
Published in final edited form as: Mol Pharm. 2015 May 8;12(6):1929–1938. doi: 10.1021/mp5006917

Figure 1.

Figure 1

Structure of DOTA-PEG4-LLP2A (A). The binding of 177Lu-DOTA-PEG4-LLP2A to integrin α4β1 was determined by saturation binding assay in B16F10 melanoma cells (n = 3 for each data point); The Kd is 4.1 ± 1.5 nM and the receptor concentration (Bmax) is 631 ± 70.2 fmol/mg (B). The binding of Ga-DOTA-PEG4-LLP2A to integrin α4β1 was determined by competitive binding assay with 64Cu-NODAGA-PEG4-LLP2A (competitor) in B16F10 melanoma cells (n = 4 for each data point); the half maximal inhibitory concentration (IC50) is 9.37 nM (95% confidence intervals 7.8–11.2), and the absolute inhibition constant (Ki) is 1.56 nM (95% confidence intervals 1.3–1.8) (C).